Evidence map›Paper›PMID 24897241›Full record

ArticleClinical pharmacology and therapeutics2014

Phenotype standardization for statin-induced myotoxicity.

A Alfirevic, D Neely, J Armitage, H Chinoy, R G Cooper, R Laaksonen, D F Carr, K M Bloch, J Fahy, A Hanson and 7 more

Registry-linked trialOpen access · hybridAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical pharmacology and therapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02984293 (Impact of LILRB5 Genotype on Immune Response to Atorvastatin), which is not on this map. Cited by 106 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed, 8 pooled it
17.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02984293 phase4completednot on this mapstarted 2017, after this paper: background citation

Impact of LILRB5 Genotype on Immune Response to Atorvastatin

TypeinterventionalSponsorUniversity of DundeeRan2017 to 2017Enrolled18ConditionsDrug IntoleranceArmsAtorvastatin, Placebo
3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 8 syntheses or guidelines pooled it, 218 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. A comprehensive review and meta-analysis of risk factors for statin-induced myopathy.European journal of clinical pharmacology · 2018 · on this map
    Pooled it
  8. Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Review
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Review
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 11 institutions in 5 countries.

A AlfirevicDepartment of Molecular and Clinical Pharmacology, TheWolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
D NeelyDepartment of Clinical Biochemistry, Newcastle upon Tyne Hospitals NHS Foundation Trust, Royal Victoria Infirmary, Newcastle upon Tyne, UK.
J ArmitageClinical Trial Service Unit, Oxford, UK.
H ChinoyCentre for Musculoskeletal Research/NIHR Manchester Musculoskeletal Biomedical Research Unit, University of Manchester, Manchester, UK.
R G CooperMRC/ARUK Institute of Ageing and Chronic Disease, Faculty of Health & Life Sciences, University of Liverpool, Liverpool, UK.
R LaaksonenZora Biosciences Ltd, Tieotie 2, Espoo, Finland.
D F CarrDepartment of Molecular and Clinical Pharmacology, TheWolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
K M BlochDepartment of Molecular and Clinical Pharmacology, TheWolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
J FahyDepartment of Molecular and Clinical Pharmacology, TheWolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
A HansonDepartment of Molecular and Clinical Pharmacology, TheWolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
Q-Y YueThe Medical Products Agency, Uppsala, Sweden.
M WadeliusDepartment of Medical Sciences, Clinical Pharmacology and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
A H Maitland-van Der ZeeDivision of Pharmacoepidemiology and Clinical Pharmacology, Utrecht University, Faculty of Science, Utrecht Institute for Pharmaceutical Sciences, Utrecht, The Netherlands.
D VooraDuke Institute for Genome Sciences and Policy, Durham, North Carolina, USA.
B M Psaty1] Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology and Health Services, University of Washington, Seattle, Washington, USA [2] Group Health Research Institute, Group Health Cooperative, Seattle, Washington, USA.
C N A PalmerMedical Research Institute, Ninewells Hospital and Medical School, Dundee, UK.
M PirmohamedDepartment of Molecular and Clinical Pharmacology, TheWolfson Centre for Personalised Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, UK.
University of Liverpool · GBDuke Institute for Health Innovation · USKaiser Permanente Washington Health Research Institute · USMedical Products Agency · SEMRC Clinical Trials Unit at UCL · GBNewcastle upon Tyne Hospitals NHS Foundation Trust · GBNIHR Oxford Musculoskeletal Biomedical Research Centre · GBNinewells Hospital · GBScience for Life Laboratory · SEUtrecht University · NLZora Biosciences (Finland) · FI

Funding

Medical Research Council MC_QA137929Medical Research Council MC_U137686853Medical Research Council MR/L006758/1Versus Arthritis 18474
6 · The paper itself

Abstract

Statins are widely used lipid-lowering drugs that are effective in reducing cardiovascular disease risk. Although they are generally well tolerated, they can cause muscle toxicity, which can lead to severe rhabdomyolysis. Research in this area has been hampered to some extent by the lack of standardized nomenclature and phenotypic definitions. We have used numerical and descriptive classifications and developed an algorithm to define statin-related myotoxicity phenotypes, including myalgia, myopathy, rhabdomyolysis, and necrotizing autoimmune myopathy.

Indexed as

Autoimmune DiseasesHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMuscular DiseasesMyalgiaMyositisPhenotypeRhabdomyolysisRisk FactorsTerminology as TopicTime FactorsHydroxymethylglutaryl-CoA Reductase Inhibitors

Identifiers

PMID24897241
PMCPMC4172546
OpenAlexW2035681453

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.